Komori
Governance4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Corporate Governance Report 2024/07/04

The report includes a skills matrix for directors and executive officers and presents schematic diagrams of the Board of Directors' composition and the timely disclosure system. Changes from the previous report are not specified in the body of the report.

Worth reading
63In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of directors11 (including 4 Outside Directors)
Number of independent officers3Number

This is the number of people reported to the exchange as independent officers. Whether someone is an outside officer and whether they qualify as independent are separate determinations.

Committee4
指名報酬委員会サステナビリティ委員会リスク管理委員会コンプライアンス委員会
Changes this time

Changes from the previous report: Not disclosed

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directors11 (including 4 Outside Directors)
Number of independent officers3
Committee指名報酬委員会(社外委員の割合はNot disclosed)、サステナビリティ委員会、リスク管理委員会、コンプライアンス委員会
Changes this timeChanges from the previous report: Not disclosed
Items this document does not state (3)
Policy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

各人が保有するスキルのうち、とりわけ強みのあるもの、または当社事業との関連性が強いものを記載したとしている。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2024/07/04 | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori